{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:41:32Z","timestamp":1763037692733,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"am","delay-in-days":440,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bulcan.2021.09.005","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:34:08Z","timestamp":1639568048000},"page":"S65-S72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S","title":["Immunoth\u00e9rapie par CAR-T cells dans le my\u00e9lome multiple\u00a0: pr\u00e9sent et futur"],"prefix":"10.1016","volume":"108","author":[{"given":"Beno\u00eet","family":"Ferment","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.09.005_bib0230","unstructured":"SPF, Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990\u00a0et 2018 - H\u00e9mopathies malignes\u00a0: \u00e9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim.\/import\/estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-france-metropolitaine-entre-1990-et-2018-hemopathies-malignes-etude-a-pa (consult\u00e9 le juin 06, 2021)."},{"issue":"26","key":"10.1016\/j.bulcan.2021.09.005_bib0235","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.bulcan.2021.09.005_bib0240","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bulcan.2021.09.005_bib0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bulcan.2021.09.005_bib0250","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3\u00a0trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.bulcan.2021.09.005_bib0255","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3\u00a0trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"7457","key":"10.1016\/j.bulcan.2021.09.005_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bulcan.2021.09.005_bib0265","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2021.09.005_bib0270","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16\u00a0is fused to the interleukin 2\u00a0gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"La\u00e2bi","year":"1992","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.bulcan.2021.09.005_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bulcan.2021.09.005_bib0280","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bulcan.2021.09.005_bib0285","unstructured":"\u00ab\u00a0B-Cell Maturation Protei n, Which Binds the Tumor Necrosis Factor Family Members BAFF and APRIL, Is Dispensable for Humoral Immune Responses\u00a0\u00bb, Molecular and Cellular Biology. https:\/\/journals.asm.org\/doi\/abs\/10.1128\/MCB.21.12.4067-4074.2001 (consult\u00e9 le juin 14, 2021)."},{"issue":"8","key":"10.1016\/j.bulcan.2021.09.005_bib0290","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.bulcan.2021.09.005_bib0295","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.09.005_bib0300","unstructured":"International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma, International Myeloma Foundation. https:\/\/www.myeloma.org\/resource-library\/international-myeloma-working-group-imwg-uniform-response-criteria-multiple (consult\u00e9 le juin 16, 2021)."},{"issue":"6","key":"10.1016\/j.bulcan.2021.09.005_bib0305","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.bulcan.2021.09.005_bib0310","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121\u00a0in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2021.09.005_bib0315","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.09.005_bib0320","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bulcan.2021.09.005_bib0325","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136748","article-title":"Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence","volume":"136","author":"Colonna","year":"2020","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2021.09.005_bib0330","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1\u00a0study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"6428","key":"10.1016\/j.bulcan.2021.09.005_bib0335","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bulcan.2021.09.005_bib0340","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020238","article-title":"The application of nanobody in CAR-T therapy","volume":"11","author":"Bao","year":"2021","journal-title":"Biomolecules"},{"year":"2020","author":"Mikkilineni","key":"10.1016\/j.bulcan.2021.09.005_bib0345"},{"issue":"6","key":"10.1016\/j.bulcan.2021.09.005_bib0350","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah et","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2021.09.005_bib0355","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.bulcan.2021.09.005_bib0360","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"\u00ab\u00a0B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma\u00a0\u00bb","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.bulcan.2021.09.005_bib0365","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bulcan.2021.09.005_bib0370","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"issue":"no Supplement 1","key":"10.1016\/j.bulcan.2021.09.005_bib0375","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-139040","article-title":"Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma","volume":"136","author":"Samur","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2021.09.005_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.bulcan.2021.09.005_bib0385","first-page":"785","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients"},{"issue":"19","key":"10.1016\/j.bulcan.2021.09.005_bib0390","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"7750","key":"10.1016\/j.bulcan.2021.09.005_bib0395","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bulcan.2021.09.005_bib0400","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1\u00a0chimeric antigen receptor redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2021.09.005_bib0405","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1\u00a0bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"issue":"26","key":"10.1016\/j.bulcan.2021.09.005_bib0410","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.09.005_bib0415","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.09.005_bib0420","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3179","article-title":"Safe harbours for the integration of new DNA in the human genome","volume":"12","author":"Sadelain","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7643","key":"10.1016\/j.bulcan.2021.09.005_bib0425","doi-asserted-by":"crossref","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9\u00a0enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bulcan.2021.09.005_bib0430","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"10.1016\/j.bulcan.2021.09.005_bib0435","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bulcan.2021.09.005_bib0440","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.bulcan.2021.09.005_bib0445","doi-asserted-by":"crossref","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bulcan.2021.09.005_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121003738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121003738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:21Z","timestamp":1757792181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121003738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0007455121003738"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.09.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoth\u00e9rapie par CAR-T cells dans le my\u00e9lome multiple\u00a0: pr\u00e9sent et futur","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}